Orthocell Limited (ASX:OCC) is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI*TM) and Autologous Chondrocyte Implantation (Ortho-ACI*TM), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro*TM, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
